Dyadic International (NASDAQ:DYAI) Earns Buy Rating from Analysts at Craig Hallum

Equities researchers at Craig Hallum started coverage on shares of Dyadic International (NASDAQ:DYAI) in a report released on Monday,Briefing.com Automated Import reports. The firm set a “buy” rating on the biotechnology company’s stock.

Dyadic International Price Performance

DYAI opened at $0.92 on Monday. The company’s 50-day simple moving average is $0.95 and its two-hundred day simple moving average is $1.10. Dyadic International has a 52-week low of $0.71 and a 52-week high of $2.20. The company has a debt-to-equity ratio of 5.40, a quick ratio of 2.02 and a current ratio of 2.02. The stock has a market capitalization of $33.29 million, a P/E ratio of -4.84 and a beta of 0.95.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). The business had revenue of $0.97 million during the quarter, compared to analyst estimates of $0.60 million. Dyadic International had a negative net margin of 134.84% and a negative return on equity of 355.39%. As a group, analysts predict that Dyadic International will post -0.18 EPS for the current year.

Institutional Investors Weigh In On Dyadic International

A number of hedge funds have recently bought and sold shares of the stock. Chapin Davis Inc. increased its holdings in shares of Dyadic International by 4.7% in the 2nd quarter. Chapin Davis Inc. now owns 882,849 shares of the biotechnology company’s stock valued at $874,000 after acquiring an additional 40,000 shares during the last quarter. Callan Capital LLC grew its holdings in Dyadic International by 86.8% in the first quarter. Callan Capital LLC now owns 50,759 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 23,585 shares during the last quarter. AlphaCore Capital LLC acquired a new stake in shares of Dyadic International during the second quarter valued at $50,000. Bank of America Corp DE lifted its position in Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares during the period. Finally, Jane Street Group LLC purchased a new position in shares of Dyadic International in the 4th quarter worth about $45,000. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.